The body-native, active form of lipoic acid, a water- and fat-soluble antioxidant that supports cellular energy and blood-sugar handling. Strongest human evidence is easing nerve symptoms in diabetes; broader metabolic and longevity benefits stay mixed and are largest in people who already have metabolic problems. Generally safe at modest doses; mild stomach upset is usual. (Full Review)

Protocol

Dose

100–300 mg/day

R-lipoic acid, as stabilized sodium R-lipoate

Timing

Morning, empty stomach

30–60 min before eating; apart from mineral supplements

Form

Sodium R-lipoate

Natural R-form; avoids the inactive S-isomer

Time to effect

Nerve symptoms

Within weeks

Neuropathy symptom relief

Metabolic markers

4–12 weeks

Inflammation and lipid changes

Longevity benefit

Not measurable

Unmeasurable in the short term

Benefits

High: Relief of diabetic nerve symptoms

Medium: Reduced systemic inflammation; improved blood lipids; modest weight and body-fat reduction

Low: Improved insulin sensitivity and glycemic markers; increased antioxidant capacity and reduced oxidative damage

Speculative: Brain aging and cognitive protection; mitochondrial rejuvenation and healthspan; skin health and anti-glycation

Contraindications

Personal or family history of insulin autoimmune syndrome

East Asian ancestry carrying HLA-DRB1*04:06

Thiamine deficiency or active alcohol-use disorder

Pregnancy or breastfeeding

Diabetics on insulin without medical supervision

Key Interactions

Antidiabetic drugs (insulin, sulfonylureas, metformin)

Thyroid medication (levothyroxine)

Chemotherapy

OTC glucose-lowering or high-dose antioxidant products

Biotin; iron and mineral supplements

Blood-sugar-lowering supplements (berberine, chromium, cinnamon, gymnema, bitter melon)

Alcohol

Risk & Side Effects

High: Gastrointestinal side effects

Medium: Hypoglycemia

Low: Insulin autoimmune syndrome; allergic and skin reactions; biotin and mineral interactions

Speculative: Metal redistribution and pro-oxidant effects; thyroid hormone considerations

Monitoring

Marker	Target	Why
Fasting glucose	70–85 mg/dL	Tracks glycemic effect and hypoglycemia risk
HbA1c	<5.3%	Reflects 3-month average blood sugar
Fasting insulin	2–5 µIU/mL	Detects insulin resistance and response
hs-CRP	<1.0 mg/L (optimal <0.5)	Tracks systemic inflammation, a key target
Triglycerides	<80 mg/dL	Monitors the most responsive lipid marker
ALT	<25 U/L	Screens liver status given metabolic use

Cadence: Baseline, at about 8–12 weeks, then every 6–12 months; more frequent glucose checks in the first weeks for those on glucose-lowering therapy.

Qualitative Assessment

Energy levels and daytime fatigue
Nerve-related sensations (tingling, numbness) if present at baseline
Appetite and hunger regulation
Cognitive clarity and focus
Absence of side effects such as nausea or episodes of low blood sugar

R-Lipoic Acid for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment